Predictive oncology strengthens business with appointment of a chief scientific officer and consolidation and expansion of its research and development arm

Eagan, minn., july 26, 2022 (globe newswire) -- predictive oncology (nasdaq: poai) today announced a strategic move to further strengthen its business and product offerings by appointing julia kirshner, ph.d., as chief scientific officer. dr. kirshner currently serves as senior vice president at predictive oncology and president of poai's zpredicta division and will be elevated to the post beginning august 1, 2022.
POAI Ratings Summary
POAI Quant Ranking